IP Library Granted Patent US 11,407,719
Granted Patent B2
US 11,407,719 · App. 16/951,701 · Granted Aug 9, 2022

Anti-inflammatory agents

Inventor: Henrik C. Hansen (Calgary, CA)
Assignee: Resverlogix Corp.
C07D239/91A61K31/517A61K31/519A61K31/5377A61K31/55A61K31/551C07D401/04C07D401/10C07D401/12C07D401/14C07D403/04C07D403/10C07D403/12C07D409/10C07D409/12C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,407,719
App. No.
16/951,701
Granted
Aug 9, 2022
Kind
B2
Abstract

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Claims (24)

1. A compound of Formula V:

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is CH;

U is C═O;

Y is oxygen;

A is C 1 -C 2 alkyl;

D may be absent or present, and if present is selected from hydroxy, pyrrolinin-1-yl, and NR 1 R 2 ;

R 1 and R 2 are independently selected from hydrogen and acetyl;

Ra 2 is hydrogen;

Ra 1 and Ra 3 are both methoxy;

Rb 2 and Rb 6 are both hydrogen; and

Rb 3 is selected from hydrogen, methyl and ethyl.

2. A compound selected from:

2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide; and

5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one;

or a pharmaceutically acceptable salt or hydrate thereof.

3. A compound that is 5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one or a pharmaceutically acceptable salt or hydrate thereof.

4. A pharmaceutical composition comprising a compound or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate according to claim 1 .

5. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or hydrate according to claim 2 .

6. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or hydrate according to claim 3 .

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 058655 FRAME 0643. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jan 27, 2022
From: RESVERLOGIX CORP.
To: HEPALINK (HONG KONG) LIMITED
Reel/Frame 058887/0288 →
SECURITY INTEREST Recorded Jan 14, 2022
From: RESVERLOGIX CORP.
To: HEPALINK (HONG KONG) LIMITED
Reel/Frame 058655/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2020
From: HANSEN, HENRIK C.
To: RESVERLOGIX CORP.
Reel/Frame 054765/0666 →
CHANGE OF ADDRESS Recorded Dec 29, 2020
From: RESVERLOGIX CORP.
To: RESVERLOGIX CORP.
Reel/Frame 054864/0342 →